Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Werewolf Therapeutics, Inc. (HOWL)
USD0.34
0.00 (-1.34%)
US NASDAQ Healthcare Biotechnology
Address
1030 Massachusetts Avenue 2138
Watertown, MA, US
Watertown, MA, US
CEO
Daniel J. Hicklin
Website
werewolftx.com
IPO
2021-04-30
CIK 1785530 ISIN US95075A1079
Description
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.34
0.00 (-1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
640.1K
Beta
0.30
Float Shares
40.64M
Free Float %
83.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.31% | -5.25% | -25.56% | -4.10% | -42.02% | -0.24% | -36.80% | -78.50% | -95.10% | -96.07% | -96.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
0.34
Low
1.00
+194.6%
Consensus
1.00
+194.6%
Median
1.00
+194.6%
High
1.00
+194.6%
DCF (Unlevered)
1.02
+201.2%
DCF (Levered)
1.04
+205.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
1.00
+194.6%
|
| All Time | 2 |
6.50
+1,814.6%
|
Quality scores
Altman Z-Score
-13.92
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+18.4% Q1'26: +30.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -1,053.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.7% Q1'26: +10.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -1.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
16.40M
est: 11.86M (+38.3%)
|
19.94M
est: 9.28M (+114.8%)
|
1.89M
est: 1.88M (+0.1%)
|
—
est: 2.52M (-100.0%)
|
8.33M
8.33M – 8.33M
+230.4% YoY
|
3.10M
3.10M – 3.10M
-62.8% YoY
|
50.0K
50.0K – 50.0K
-98.4% YoY
|
18.00M
18.00M – 18.00M
+35,900.0% YoY
|
| EBITDA |
-51.30M
est: -2.37M (-2,062.5%)
|
-32.47M
est: -1.86M (-1,648.6%)
|
-64.05M
est: -376.5K (-16,911.3%)
|
-59.04M
est: -504.5K (-11,603.6%)
|
-1.67M
-1.67M – -1.67M
-230.4% YoY
|
-620.0K
-620.0K – -620.0K
+62.8% YoY
|
-10.0K
-10.0K – -10.0K
+98.4% YoY
|
-3.60M
-3.60M – -3.60M
-35,903.6% YoY
|
| EBIT |
-53.81M
est: -2.37M (-2,168.3%)
|
-34.23M
est: -1.86M (-1,743.6%)
|
-65.86M
est: -376.5K (-17,393.2%)
|
-60.68M
est: -504.5K (-11,927.5%)
|
-1.67M
-1.67M – -1.67M
-230.4% YoY
|
-620.0K
-620.0K – -620.0K
+62.8% YoY
|
-10.0K
-10.0K – -10.0K
+98.4% YoY
|
-3.60M
-3.60M – -3.60M
-35,903.6% YoY
|
| Net Income |
-53.81M
est: -91.14M (+41.0%)
|
-37.37M
est: -63.93M (+41.5%)
|
-70.52M
est: -73.14M (+3.6%)
|
-60.82M
est: -70.21M (+13.4%)
|
-41.98M
-55.23M – -28.74M
+40.2% YoY
|
-74.43M
-102.66M – -46.20M
-77.3% YoY
|
-68.81M
-95.96M – -41.66M
+7.5% YoY
|
-46.11M
-46.11M – -46.11M
+33.0% YoY
|
| SGA |
21.50M
est: 34.04M (-36.8%)
|
18.67M
est: 26.64M (-29.9%)
|
19.05M
est: 5.40M (+252.5%)
|
15.85M
est: 7.24M (+118.9%)
|
23.92M
23.92M – 23.92M
+230.4% YoY
|
8.90M
8.90M – 8.90M
-62.8% YoY
|
143.5K
143.5K – 143.5K
-98.4% YoY
|
51.66M
51.66M – 51.66M
+35,900.2% YoY
|
| EPS |
-1.86
est: -2.08 (+10.5%)
|
-1.05
est: -1.37 (+23.1%)
|
-1.63
est: -1.50 (-8.9%)
|
-1.32
est: -1.51 (+12.3%)
|
-0.89
-1.18 – -0.61
+40.9% YoY
|
-1.60
-2.19 – -0.99
-79.2% YoY
|
-1.47
-2.05 – -0.89
+7.8% YoY
|
-0.99
-0.99 – -0.99
+33.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-64.10M
OE per share TTM
-1.41
Owner's Yield
-214.23%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
202.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
50
Total invested
9.34M
Insider transactions (90d)
6
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ansbert Gadicke | 6.73M | 24.40% | — | 6.73M | — | 6.73M | IN | — | 2021-05-14 | ↗ |
| 2 | Luke Evnin | 4.32M | 15.70% | — | 4.32M | — | 4.32M | IN | — | 2021-05-14 | ↗ |
| 3 | Peter Kolchinsky | 4.30M | 14.57% | — | 4.30M | — | 10.00 | HC, IN | United States | 2022-08-12 | ↗ |
| 4 | RA Capital Management, L.P. | 4.30M | 14.57% | — | 4.30M | — | 10.00 | IA, PN | Delaware | 2022-08-12 | ↗ |
| 5 | Rajeev Shah | 4.30M | 14.57% | — | 4.30M | — | 10.00 | HC, IN | United States | 2022-08-12 | ↗ |
| 6 | RA Capital Healthcare Fund, L.P. | 3.86M | 13.07% | — | 3.86M | — | 10.00 | PN | United States | 2022-08-12 | ↗ |
| 7 | MPM BioVentures 2014 LLC | 3.21M | 11.70% | — | 3.21M | — | 3.21M | OO | — | 2021-05-14 | ↗ |
| 8 | Todd Foley | 3.21M | 11.70% | — | 3.21M | — | 3.21M | IN | — | 2021-05-14 | ↗ |
| 9 | MPM BioVentures 2014 GP LLC | 3.11M | 11.30% | — | 3.11M | — | 3.11M | OO | — | 2021-05-14 | ↗ |
| 10 | Adage Capital Management, L.P. | 3.03M | 8.38% | — | 3.03M | — | — | IA, PN | Delaware | 2023-12-21 | ↗ |
| 11 | Adage Capital Partners GP, L.L.C. | 3.03M | 8.38% | — | 3.03M | — | — | OO | Delaware | 2023-12-21 | ↗ |
| 12 | Adage Capital Partners, L.P. | 3.03M | 8.38% | — | 3.03M | — | — | PN | Delaware | 2023-12-21 | ↗ |
| 13 | Phillip Gross | 3.03M | 8.38% | — | 3.03M | — | — | IN | United States | 2023-12-21 | ↗ |
| 14 | Robert Atchinson | 3.03M | 8.38% | — | 3.03M | — | — | IN | United States | 2023-12-21 | ↗ |
| 15 | MPM Oncology Impact Management GP LLC | 2.41M | 8.80% | 2.41M | — | 2.41M | — | OO | — | 2021-05-14 | ↗ |
| 16 | MPM Oncology Impact Management LP | 2.41M | 8.80% | 2.41M | — | 2.41M | — | PN | — | 2021-05-14 | ↗ |
| 17 | Oncology Impact Fund (Cayman) Management LP | 2.41M | 8.80% | 2.41M | — | 2.41M | — | PN | — | 2021-05-14 | ↗ |
| 18 | UBS Oncology Impact Fund, L.P. | 2.41M | 8.80% | 2.41M | — | 2.41M | — | PN | — | 2021-05-14 | ↗ |
| 19 | BANK OF AMERICA CORPORATION56-0906609 | 2.10M | 5.80% | — | 2.08M | — | 2.10M | HC | — | 2024-02-13 | ↗ |
| 20 | Taiho Ventures LLC | 2.07M | 7.51% | 2.07M | — | 2.07M | — | CO | — | 2021-05-13 | ↗ |
| 21 | David Rosen | 1.84M | 5.97% | — | 1.84M | — | — | IN | United States of America | 2023-02-10 | ↗ |
| 22 | LP | 1.84M | 5.97% | — | 1.84M | — | — | IA, PN | State of Delaware | 2023-02-10 | ↗ |
| 23 | Longwood Fund III GP, LLC | 1.68M | 6.10% | — | 1.68M | — | 1.68M | OO | Delaware | 2021-05-14 | ↗ |
| 24 | Longwood Fund III, L.P. | 1.68M | 6.10% | — | 1.68M | — | 1.68M | PN | Delaware | 2021-05-14 | ↗ |
| 25 | Company, L.P. | 958.1K | 3.47% | — | 958.1K | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 26 | Deerfield Mgmt, L.P. | 958.1K | 3.47% | — | 958.1K | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 27 | Deerfield Partners, L.P. | 958.1K | 3.47% | — | 958.1K | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 28 | James E. Flynn | 958.1K | 3.47% | — | 958.1K | — | — | IN | Delaware | 2022-02-11 | ↗ |
| 29 | MPM Oncology Innovations Fund GP LLC | 640.1K | 2.30% | — | 640.1K | — | 640.1K | OO | — | 2021-05-14 | ↗ |
| 30 | MPM Oncology Innovations Fund, L.P. | 640.1K | 2.30% | 640.1K | — | 640.1K | — | PN | — | 2021-05-14 | ↗ |
| 31 | Stephen Curtis | 640.1K | 2.30% | — | 640.1K | — | 640.1K | IN | — | 2021-05-14 | ↗ |
| 32 | MPM Asset Management LLC | 461.4K | 1.70% | 461.4K | — | 461.4K | — | OO | — | 2021-05-14 | ↗ |
| 33 | MPM BioVentures 2014 (B), L.P. | 194.7K | 0.70% | 194.7K | — | 194.7K | — | PN | — | 2021-05-14 | ↗ |
| 34 | MPM Asset Management Investors BV2014 LLC | 100.5K | 0.40% | 100.5K | — | 100.5K | — | OO | — | 2021-05-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
50
-12 vs prev Q
New positions
7
Closed positions
19
Increased
21
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 6.68M +— (+0.0%) | 4.23M -8.9M (-67.8%) | 14.69% -0.160 pp | 0.04% -0.119 pp | USD12.01 -94.8% | 19 qtrs — |
| 2 | VANGUARD GROUP INC | 1.41M +— (+0.0%) | 892.7K -1.9M (-67.8%) | 3.10% -0.034 pp | 0.00% +0.000 pp | USD5.89 -89.3% | 19 qtrs — |
| 3 | BIOIMPACT CAPITAL LLC | 1.39M -1.0M (-42.1%) | 883.5K -3.9M (-81.4%) | 3.06% -2.291 pp | 0.10% -0.676 pp | USD17.30 -96.4% | 19 qtrs — |
| 4 | BANK OF AMERICA CORP /DE/ | 737.6K -1.1M (-59.7%) | 466.9K -3.1M (-87.1%) | 1.62% -2.447 pp | 0.00% 0.000 pp | USD2.49 -74.7% | 19 qtrs — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 677.8K +221.8K (+48.6%) | 429.4K -469.0K (-52.2%) | 1.49% +0.477 pp | 0.00% -0.001 pp | USD1.27 -50.4% | 15 qtrs — |
| 6 | LYNX1 CAPITAL MANAGEMENT LP | 655.9K +655.9K (+100.0%) | 415.5K +415.5K (+100.0%) | 1.44% +1.443 pp | 0.08% +0.084 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 7 | SPHERA FUNDS MANAGEMENT LTD. | 626.8K +— (+0.0%) | 397.1K -837.7K (-67.8%) | 1.38% -0.015 pp | 0.08% -0.184 pp | USD16.55 -96.2% | 19 qtrs — |
| 8 | DC FUNDS, LP | 589.1K +— (+0.0%) | 373.2K -787.3K (-67.8%) | 1.30% -0.014 pp | 25.69% -11.630 pp | USD17.26 -96.3% | 19 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 335.9K +5.1K (+1.5%) | 212.8K -439.0K (-67.3%) | 0.74% +0.003 pp | 0.00% +0.000 pp | USD3.91 -83.9% | 19 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 240.1K -76.9K (-24.3%) | 152.1K -472.5K (-75.6%) | 0.53% -0.177 pp | 0.00% 0.000 pp | USD2.50 -74.8% | 16 qtrs — |
| 11 | ALYESKA INVESTMENT GROUP, L.P. | 235.7K +— (+0.0%) | 149.3K -315.0K (-67.8%) | 0.52% -0.006 pp | 0.00% -0.001 pp | USD9.73 -93.5% | 19 qtrs — |
| 12 | JANE STREET GROUP, LLC | 157.3K -111.3K (-41.4%) | 99.7K -429.4K (-81.2%) | 0.35% -0.251 pp | 0.00% 0.000 pp | USD1.09 -42.2% | 9 qtrs — |
| 13 | STATE STREET CORP | 119.2K +— (+0.0%) | 75.5K -159.3K (-67.8%) | 0.26% -0.003 pp | 0.00% +0.000 pp | USD2.77 -77.3% | 19 qtrs — |
| 14 | BLACKROCK, INC. | 101.6K +320.0 (+0.3%) | 64.4K -135.2K (-67.7%) | 0.22% -0.002 pp | 0.00% +0.000 pp | USD2.09 -69.9% | 6 qtrs — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 99.8K +6.8K (+7.3%) | 63.2K -120.0K (-65.5%) | 0.22% +0.013 pp | 0.00% +0.000 pp | USD1.29 -51.2% | 5 qtrs — |
| 16 | NORTHERN TRUST CORP | 86.9K +21.0K (+31.9%) | 55.0K -74.7K (-57.6%) | 0.19% +0.045 pp | 0.00% +0.000 pp | USD2.32 -72.8% | 19 qtrs — |
| 17 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 77.0K -25.0K (-24.5%) | 48.8K -152.2K (-75.7%) | 0.17% -0.057 pp | 0.00% -0.003 pp | USD1.65 -61.8% | 15 qtrs — |
| 18 | UBS GROUP AG | 60.7K +47.9K (+375.2%) | 38.4K +13.3K (+52.7%) | 0.13% +0.105 pp | 0.00% +0.000 pp | USD0.91 -30.8% | 19 qtrs — |
| 19 | VONTOBEL HOLDING LTD. | 60.0K +24.0K (+66.7%) | 38.0K -32.9K (-46.4%) | 0.13% +0.052 pp | 0.00% 0.000 pp | USD0.85 -25.9% | 4 qtrs — |
| 20 | REGAL INVESTMENT ADVISORS LLC | 52.6K +25.4K (+93.3%) | 33.3K -20.3K (-37.8%) | 0.12% +0.055 pp | 0.00% -0.002 pp | USD1.25 -49.6% | 6 qtrs — |
| 21 | EDGEWOOD MANAGEMENT LLC | 50.0K +— (+0.0%) | 31.7K -66.8K (-67.8%) | 0.11% -0.001 pp | 0.00% 0.000 pp | USD2.60 -75.8% | 12 qtrs — |
| 22 | MORGAN STANLEY | 46.0K +26.8K (+138.9%) | 29.1K -8.8K (-23.2%) | 0.10% +0.058 pp | 0.00% +0.000 pp | USD1.51 -58.3% | 19 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 34.1K -26.3K (-43.5%) | 21.6K -97.3K (-81.8%) | 0.07% -0.059 pp | 0.00% +0.000 pp | USD2.31 -72.7% | 8 qtrs — |
| 24 | SIMPLEX TRADING, LLC | 24.1K +8.4K (+53.8%) | 15.3K -14.8K (-49.2%) | 0.05% +0.018 pp | 0.00% +0.000 pp | USD1.31 -51.9% | 11 qtrs — |
| 25 | CERTUITY, LLC | 15.0K +— (+0.0%) | 9.5K -20.0K (-67.8%) | 0.03% 0.000 pp | 0.00% -0.001 pp | USD3.28 -80.8% | 9 qtrs — |
| 26 | DELTA INVESTMENT MANAGEMENT, LLC | 14.9K +14.9K (+100.0%) | 9.5K +9.5K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.002 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 27 | POINT72 ASSET MANAGEMENT, L.P. | 14.5K +14.5K (+100.0%) | 9.2K +9.2K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 28 | BARCLAYS PLC | 13.2K -41.6K (-75.9%) | 8.4K -107.8K (-92.8%) | 0.03% -0.093 pp | 0.00% +0.000 pp | USD2.05 -69.3% | 8 qtrs — |
| 29 | LARSON FINANCIAL GROUP LLC | 13.1K +3.1K (+30.5%) | 8.3K -11.4K (-58.0%) | 0.03% +0.007 pp | 0.00% 0.000 pp | USD1.28 -50.8% | 5 qtrs — |
| 30 | HBK SORCE ADVISORY LLC | 13.2K +— (+0.0%) | 8.1K -15.2K (-65.2%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD2.46 -74.4% | 12 qtrs — |
| 31 | ENGINEERS GATE MANAGER LP | 12.2K +12.2K (+100.0%) | 7.7K +7.7K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 32 | HIGHLINE WEALTH PARTNERS LLC | 12.0K +7.0K (+140.0%) | 7.6K -2.2K (-22.8%) | 0.03% +0.015 pp | 0.00% -0.001 pp | USD0.82 -23.2% | 3 qtrs — |
| 33 | RANCH CAPITAL ADVISORS INC. | 12.0K +12.0K (+100.0%) | 7.6K +7.6K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.003 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 34 | STONEX GROUP INC. | 10.5K +10.5K (+100.0%) | 6.7K +6.7K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 35 | TWO SIGMA ADVISERS, LP | 10.3K -24.3K (-70.2%) | 6.5K -61.6K (-90.4%) | 0.02% -0.054 pp | 0.00% 0.000 pp | USD4.41 -85.7% | 9 qtrs — |
| 36 | CETERA INVESTMENT ADVISERS | 10.2K +— (+0.0%) | 6.5K -13.6K (-67.8%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.97 -68.0% | 2 qtrs — |
| 37 | ADVISOR GROUP HOLDINGS, INC. | 8.6K -1.0K (-10.4%) | 5.4K -7.9K (-59.1%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.42 -55.6% | 5 qtrs — |
| 38 | FINANCIAL PERSPECTIVES, INC | 6.8K +— (+0.0%) | 4.3K -9.0K (-67.8%) | 0.01% 0.000 pp | 0.00% -0.003 pp | USD3.54 -82.2% | 19 qtrs — |
| 39 | TFC FINANCIAL MANAGEMENT, INC. | 4.5K +2.0K (+80.0%) | 2.9K -2.1K (-42.1%) | 0.01% +0.004 pp | 0.00% 0.000 pp | USD1.39 -54.7% | 7 qtrs — |
| 40 | FEDERATED HERMES, INC. | 4.4K +— (+0.0%) | 2.8K -5.9K (-67.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.01 -37.6% | 5 qtrs — |
| 41 | FMR LLC | 3.6K -7.7K (-67.8%) | 2.3K -19.9K (-89.7%) | 0.01% -0.017 pp | 0.00% +0.000 pp | USD1.21 -47.9% | 7 qtrs — |
| 42 | JPMORGAN CHASE & CO | 2.1K +949.0 (+84.5%) | 1.3K -899.0 (-40.6%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.65 -61.8% | 19 qtrs — |
| 43 | GROUP ONE TRADING, L.P. | 1.9K -800.0 (-30.0%) | 1.2K -4.1K (-77.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.97 -68.0% | 2 qtrs — |
| 44 | BNP PARIBAS ARBITRAGE, SNC | 792.00 -1.0 (-0.1%) | 502.00 -1.1K (-67.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.45 -56.6% | 5 qtrs — |
| 45 | NISA INVESTMENT ADVISORS, LLC | 345.00 -1.0K (-74.9%) | 219.00 -2.5K (-91.9%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.09 -42.2% | 6 qtrs — |
| 46 | SRS CAPITAL ADVISORS, INC. | 39.00 -29.0 (-42.6%) | 25.00 -108.0 (-81.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.95 -67.7% | 2 qtrs — |
| 47 | SBI SECURITIES CO., LTD. | 40.00 -1.0 (-2.4%) | 25.00 -56.0 (-69.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.45 -56.6% | 5 qtrs — |
| 48 | OPTIVER HOLDING B.V. | 22.00 +— (+0.0%) | 14.00 -29.0 (-67.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.95 -67.7% | 2 qtrs — |
| 49 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 4.00 +4.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +26.0% | 1 qtrs NEW |
| 50 | CITIGROUP INC | 1.00 -8.7K (-100.0%) | 1.00 -17.1K (-100.0%) | 0.00% -0.019 pp | 0.00% +0.000 pp | USD2.00 -68.5% | 8 qtrs — |
| 51 | ACADIAN ASSET MANAGEMENT LLC | — -34.3K (-100.0%) | — -67.0K (-100.0%) | 0.00% -0.076 pp | 0.00% 0.000 pp | USD— | 13 qtrs SOLD |
| 52 | CITADEL ADVISORS LLC | — -154.5K (-100.0%) | — -304.4K (-100.0%) | 0.00% -0.344 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 53 | PFM HEALTH SCIENCES, LP | — -401.1K (-100.0%) | — -790.2K (-100.0%) | 0.00% -0.892 pp | 0.00% -0.061 pp | USD— | 19 qtrs SOLD |
| 54 | PLANTE MORAN FINANCIAL ADVISORS, LLC | — -50.0 (-100.0%) | — -99.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 55 | EVERSOURCE WEALTH ADVISORS, LLC | — -35.0 (-100.0%) | — -69.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 56 | QUBE RESEARCH & TECHNOLOGIES LTD | — -29.3K (-100.0%) | — -57.6K (-100.0%) | 0.00% -0.065 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 57 | AQR CAPITAL MANAGEMENT LLC | — -17.8K (-100.0%) | — -35.1K (-100.0%) | 0.00% -0.040 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 58 | TOWER RESEARCH CAPITAL LLC (TRC) | — -6.0K (-100.0%) | — -11.8K (-100.0%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD— | 19 qtrs SOLD |
| 59 | CWM, LLC | — -1.6K (-100.0%) | — -3.0K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 60 | TWO SIGMA INVESTMENTS, LP | — -20.1K (-100.0%) | — -39.7K (-100.0%) | 0.00% -0.045 pp | 0.00% 0.000 pp | USD— | 13 qtrs SOLD |
| 61 | ADVISORY SERVICES NETWORK, LLC | — -157.0 (-100.0%) | — -309.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 62 | HRT FINANCIAL LP | — -39.9K (-100.0%) | — -78.0K (-100.0%) | 0.00% -0.089 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 63 | VIRTU FINANCIAL LLC | — -12.2K (-100.0%) | — -24.0K (-100.0%) | 0.00% -0.027 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 64 | RAYMOND JAMES FINANCIAL INC | — -14.4K (-100.0%) | — -28.4K (-100.0%) | 0.00% -0.032 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 65 | ROSSBY FINANCIAL, LCC | — -860.0 (-100.0%) | — -1.7K (-100.0%) | 0.00% -0.002 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 66 | ROYAL BANK OF CANADA | — -806.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 151.4K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 833.17 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.3K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 168.97 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 391.0K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 857.28 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 466.73 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 188.37 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 20.79 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 2.93 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
6
Shares acquired
—
Shares disposed
480.5K
Cash buys
—
Cash sales
6.00
Net activity
-480,530
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 47,963 | 0.72 | 34.5K | 1,679,330 | I | ↗ |
| 2026-05-01 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 58,394 | 0.73 | 42.6K | 1,727,293 | I | ↗ |
| 2026-04-30 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 168,262 | 0.72 | 121.1K | 1,785,687 | I | ↗ |
| 2026-04-29 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 56,559 | 0.69 | 39.0K | 1,953,949 | I | ↗ |
| 2026-04-28 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 95,412 | 0.73 | 69.7K | 2,010,508 | I | ↗ |
| 2026-04-27 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 53,940 | 0.85 | 45.8K | 2,105,920 | I | ↗ |
| 2026-02-13 | Urban Michael J. | Officer | — | — | Stock Option (right to buy) | 10,000 | 1.57 | 15.7K | 0 | D | ↗ |
| 2026-01-16 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 38,782 | 0.54 | 20.9K | 2,159,860 | I | ↗ |
| 2026-01-15 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 37,413 | 0.55 | 20.6K | 2,198,642 | I | ↗ |
| 2026-01-14 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 30,616 | 0.57 | 17.5K | 2,236,055 | I | ↗ |
| 2026-01-13 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 43,198 | 0.55 | 23.8K | 2,266,671 | I | ↗ |
| 2026-01-12 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 58,980 | 0.57 | 33.6K | 2,309,869 | I | ↗ |
| 2026-01-09 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 24,678 | 0.61 | 15.1K | 2,368,849 | I | ↗ |
| 2026-01-08 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 7,716 | 0.63 | 4.9K | 2,393,527 | I | ↗ |
| 2026-01-07 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 11,915 | 0.64 | 7.6K | 2,401,243 | I | ↗ |
| 2026-01-06 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 40,761 | 0.65 | 26.5K | 2,413,158 | I | ↗ |
| 2026-01-05 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 18,378 | 0.64 | 11.8K | 2,453,919 | I | ↗ |
| 2026-01-02 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 18,568 | 0.63 | 11.7K | 2,472,297 | I | ↗ |
| 2025-12-31 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 24,962 | 0.62 | 15.5K | 2,490,865 | I | ↗ |
| 2025-12-30 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 34,847 | 0.61 | 21.3K | 2,515,827 | I | ↗ |
| 2025-12-29 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 108,606 | 0.61 | 66.2K | 2,550,674 | I | ↗ |
| 2025-12-26 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 35,632 | 0.63 | 22.4K | 2,659,280 | I | ↗ |
| 2025-12-24 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 16,310 | 0.65 | 10.6K | 2,694,912 | I | ↗ |
| 2025-12-23 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 71,428 | 0.63 | 45.0K | 2,711,222 | I | ↗ |
| 2025-12-22 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 59,307 | 0.69 | 40.9K | 2,782,650 | I | ↗ |
| 2025-12-17 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 9,983 | 1.14 | 11.4K | 2,841,957 | I | ↗ |
| 2025-12-16 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 14,548 | 1.05 | 15.3K | 2,851,940 | I | ↗ |
| 2025-12-15 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 23,640 | 1.07 | 25.3K | 2,866,488 | I | ↗ |
| 2025-12-12 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 17,858 | 1.08 | 19.3K | 2,890,128 | I | ↗ |
| 2025-12-11 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 28,009 | 1.07 | 30.0K | 2,907,986 | I | ↗ |
| 2025-12-10 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 37,104 | 1.06 | 39.3K | 2,935,995 | I | ↗ |
| 2025-12-09 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 44,570 | 1.01 | 45.0K | 2,973,099 | I | ↗ |
| 2025-12-08 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 34,041 | 0.99 | 33.7K | 3,017,669 | I | ↗ |
| 2025-12-05 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 16,568 | 0.97 | 16.1K | 3,051,710 | I | ↗ |
| 2025-12-04 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 83,230 | 0.97 | 80.7K | 4,784,111 | I | ↗ |
| 2025-12-04 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 83,230 | 0.97 | 80.7K | 4,784,111 | I | ↗ |
| 2025-12-04 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 53,416 | 0.97 | 51.8K | 3,068,278 | I | ↗ |
| 2025-12-03 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 57,225 | 0.87 | 49.8K | 4,867,341 | I | ↗ |
| 2025-12-03 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 57,225 | 0.87 | 49.8K | 4,867,341 | I | ↗ |
| 2025-12-03 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 36,726 | 0.87 | 32.0K | 3,121,694 | I | ↗ |
| 2025-12-02 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 59,277 | 0.89 | 52.8K | 4,924,566 | I | ↗ |
| 2025-12-02 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 59,277 | 0.89 | 52.8K | 4,924,566 | I | ↗ |
| 2025-12-02 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 38,043 | 0.89 | 33.9K | 3,158,420 | I | ↗ |
| 2025-12-01 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 60,917 | 0.94 | 57.3K | 4,983,843 | I | ↗ |
| 2025-12-01 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 60,917 | 0.94 | 57.3K | 4,983,843 | I | ↗ |
| 2025-12-01 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 39,096 | 0.94 | 36.8K | 3,196,463 | I | ↗ |
| 2025-11-28 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 20,277 | 0.99 | 20.1K | 5,044,760 | I | ↗ |
| 2025-11-28 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 20,277 | 0.99 | 20.1K | 5,044,760 | I | ↗ |
| 2025-11-28 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 13,014 | 0.99 | 12.9K | 3,235,559 | I | ↗ |
| 2025-11-26 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 60,733 | 0.98 | 59.5K | 5,065,037 | I | ↗ |
| 2025-11-26 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 60,733 | 0.98 | 59.5K | 5,065,037 | I | ↗ |
| 2025-11-26 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 38,978 | 0.98 | 38.2K | 3,248,573 | I | ↗ |
| 2025-11-25 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 42,533 | 0.92 | 39.1K | 5,125,770 | I | ↗ |
| 2025-11-25 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 42,533 | 0.92 | 39.1K | 5,125,770 | I | ↗ |
| 2025-11-25 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 27,297 | 0.92 | 25.1K | 3,287,551 | I | ↗ |
| 2025-11-24 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 88,802 | 0.98 | 87.0K | 5,168,303 | I | ↗ |
| 2025-11-24 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 88,802 | 0.98 | 87.0K | 5,168,303 | I | ↗ |
| 2025-11-24 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 56,992 | 0.98 | 55.9K | 3,314,848 | I | ↗ |
| 2025-11-21 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 64,331 | 0.83 | 53.4K | 5,257,105 | I | ↗ |
| 2025-11-21 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 64,331 | 0.83 | 53.4K | 5,257,105 | I | ↗ |
| 2025-11-21 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 41,287 | 0.83 | 34.3K | 3,371,840 | I | ↗ |
| 2025-11-20 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 41,152 | 0.89 | 36.6K | 5,321,436 | I | ↗ |
| 2025-11-20 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 41,152 | 0.89 | 36.6K | 5,321,436 | I | ↗ |
| 2025-11-20 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 26,411 | 0.89 | 23.5K | 3,413,127 | I | ↗ |
| 2025-11-19 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 66,324 | 0.94 | 62.3K | 5,362,588 | I | ↗ |
| 2025-11-19 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 66,324 | 0.94 | 62.3K | 5,362,588 | I | ↗ |
| 2025-11-19 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 42,566 | 0.94 | 40.0K | 3,439,538 | I | ↗ |
| 2025-11-18 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 52,627 | 0.93 | 48.9K | 5,428,912 | I | ↗ |
| 2025-11-18 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 52,627 | 0.93 | 48.9K | 5,428,912 | I | ↗ |
| 2025-11-18 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 33,776 | 0.93 | 31.4K | 3,482,104 | I | ↗ |
| 2025-11-17 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 57,061 | 0.95 | 54.2K | 5,481,539 | I | ↗ |
| 2025-11-17 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 57,061 | 0.95 | 54.2K | 5,481,539 | I | ↗ |
| 2025-11-17 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 36,621 | 0.95 | 34.8K | 3,515,880 | I | ↗ |
| 2025-11-14 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 61,640 | 0.93 | 57.3K | 5,538,600 | I | ↗ |
| 2025-11-14 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 61,640 | 0.93 | 57.3K | 5,538,600 | I | ↗ |
| 2025-11-14 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 39,560 | 0.93 | 36.8K | 3,552,501 | I | ↗ |
| 2025-11-13 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 90,951 | 0.98 | 89.1K | 5,600,240 | I | ↗ |
| 2025-11-13 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 90,951 | 0.98 | 89.1K | 5,600,240 | I | ↗ |
| 2025-11-13 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 58,372 | 0.98 | 57.2K | 3,592,061 | I | ↗ |
| 2025-11-12 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 40,669 | 1.09 | 44.3K | 5,691,191 | I | ↗ |
| 2025-11-12 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 40,669 | 1.09 | 44.3K | 5,691,191 | I | ↗ |
| 2025-11-12 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 26,101 | 1.09 | 28.5K | 3,650,433 | I | ↗ |
| 2025-11-11 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 55,810 | 1.14 | 63.6K | 5,731,860 | I | ↗ |
| 2025-11-11 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 55,810 | 1.14 | 63.6K | 5,731,860 | I | ↗ |
| 2025-11-11 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 35,818 | 1.14 | 40.8K | 3,676,534 | I | ↗ |
| 2025-11-10 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 48,570 | 1.18 | 57.3K | 5,787,670 | I | ↗ |
| 2025-11-10 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 48,570 | 1.18 | 57.3K | 5,787,670 | I | ↗ |
| 2025-11-10 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 31,172 | 1.18 | 36.8K | 3,712,352 | I | ↗ |
| 2025-11-07 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 68,480 | 1.11 | 76.0K | 5,836,240 | I | ↗ |
| 2025-11-07 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 68,480 | 1.11 | 76.0K | 5,836,240 | I | ↗ |
| 2025-11-07 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 43,950 | 1.11 | 48.8K | 3,743,524 | I | ↗ |
| 2025-11-06 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 54,452 | 1.21 | 65.9K | 5,904,720 | I | ↗ |
| 2025-11-06 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 54,452 | 1.21 | 65.9K | 5,904,720 | I | ↗ |
| 2025-11-06 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 34,947 | 1.21 | 42.3K | 3,787,474 | I | ↗ |
| 2025-11-05 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 47,950 | 1.22 | 58.5K | 5,959,172 | I | ↗ |
| 2025-11-05 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 47,950 | 1.22 | 58.5K | 5,959,172 | I | ↗ |
| 2025-11-05 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 30,774 | 1.22 | 37.5K | 3,822,421 | I | ↗ |
| 2025-11-04 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 140,488 | 1.22 | 171.4K | 6,007,122 | I | ↗ |
| 2025-11-04 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 140,488 | 1.22 | 171.4K | 6,007,122 | I | ↗ |
| 2025-11-04 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 90,164 | 1.22 | 110.0K | 3,853,195 | I | ↗ |
| 2025-11-03 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 94,063 | 1.29 | 121.3K | 6,147,610 | I | ↗ |
| 2025-11-03 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 94,063 | 1.29 | 121.3K | 6,147,610 | I | ↗ |
| 2025-11-03 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 60,369 | 1.29 | 77.9K | 3,943,359 | I | ↗ |
| 2025-10-31 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 114,044 | 1.28 | 146.0K | 6,241,673 | I | ↗ |
| 2025-10-31 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 114,044 | 1.28 | 146.0K | 6,241,673 | I | ↗ |
| 2025-10-31 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 73,192 | 1.28 | 93.7K | 4,003,728 | I | ↗ |
| 2025-10-30 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 86,936 | 1.43 | 124.3K | 6,355,717 | I | ↗ |
| 2025-10-30 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 86,936 | 1.43 | 124.3K | 6,355,717 | I | ↗ |
| 2025-10-30 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 55,795 | 1.43 | 79.8K | 4,076,920 | I | ↗ |
| 2025-10-29 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 134,240 | 1.55 | 208.1K | 6,442,653 | I | ↗ |
| 2025-10-29 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 134,240 | 1.55 | 208.1K | 6,442,653 | I | ↗ |
| 2025-10-29 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 86,154 | 1.55 | 133.5K | 4,132,715 | I | ↗ |
| 2025-10-28 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 69,068 | 1.64 | 113.3K | 6,576,893 | I | ↗ |
| 2025-10-28 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 69,068 | 1.64 | 113.3K | 6,576,893 | I | ↗ |
| 2025-10-28 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 44,327 | 1.64 | 72.7K | 4,218,869 | I | ↗ |
| 2025-10-27 | MPM BioVentures 2014, L.P. | 10% Owner | S-Sale | D | Common Stock | 72,709 | 1.72 | 125.1K | 6,645,961 | I | ↗ |
| 2025-10-27 | GADICKE ANSBERT | 10% Owner | S-Sale | D | Common Stock | 72,709 | 1.72 | 125.1K | 6,645,961 | I | ↗ |
| 2025-10-27 | EVNIN LUKE | Director | S-Sale | D | Common Stock | 46,664 | 1.72 | 80.3K | 4,263,196 | I | ↗ |
| 2025-06-12 | Singhal Anil K. | Director | A-Award | A | Stock Option (right to buy) | 8,358 | 1.29 | 10.8K | 8,358 | D | ↗ |
| 2025-06-12 | Sherman Michael A. | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-12 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-12 | Lazarus Alon | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-12 | EVNIN LUKE | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-12 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-12 | Atkins Michael B. | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.29 | 34.8K | 27,000 | D | ↗ |
| 2025-06-11 | Singhal Anil K. | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 1.23 | 11.1K | 9,000 | D | ↗ |
| 2025-05-14 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 162,539 | 0.98 | 159.3K | 6,237,482 | I | ↗ |
| 2025-05-13 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 52,974 | 0.98 | 51.9K | 6,074,943 | I | ↗ |
| 2025-05-12 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 320,913 | 0.86 | 276.0K | 6,021,969 | I | ↗ |
| 2025-05-01 | Bloom Steven H. | Officer | A-Award | A | Stock Option (right to buy) | 201,720 | 0.87 | 175.5K | 201,720 | D | ↗ |
| 2025-04-16 | Bloom Steven H. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-27 | MPM BioVentures 2014, L.P. | 10% Owner | X-InTheMoney | D | Warrant (Right to Buy) | 18,743 | 0.09 | 1.7K | 0 | I | ↗ |
| 2025-03-27 | GADICKE ANSBERT | 10% Owner | X-InTheMoney | D | Warrant (Right to Buy) | 42,842 | 0.09 | 3.9K | 0 | I | ↗ |
| 2025-03-27 | EVNIN LUKE | Director / 10% Owner | X-InTheMoney | D | Warrant (Right to Buy) | 24,098 | 0.09 | 2.2K | 0 | I | ↗ |
| 2025-02-19 | Singhal Anil K. | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.40 | 63.0K | 45,000 | D | ↗ |
| 2025-01-02 | Trost Timothy W. | Officer | A-Award | A | Stock Option (right to buy) | 60,358 | 1.56 | 94.2K | 60,358 | D | ↗ |
| 2025-01-02 | Lubman Ellen | Officer | A-Award | A | Stock Option (right to buy) | 131,900 | 1.56 | 205.8K | 131,900 | D | ↗ |
| 2025-01-02 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 1.56 | 234.0K | 150,000 | D | ↗ |
| 2025-01-02 | Isaacs Randi | Officer | A-Award | A | Stock Option (right to buy) | 68,151 | 1.56 | 106.3K | 68,151 | D | ↗ |
| 2025-01-02 | HICKLIN DANIEL J | Director / Officer | A-Award | A | Stock Option (right to buy) | 592,690 | 1.56 | 924.6K | 592,690 | D | ↗ |
| 2024-05-24 | Sherman Michael A. | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | Lazarus Alon | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | EVNIN LUKE | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | DiRocco Derek | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 4.88 | 85.4K | 17,500 | — | ↗ |
| 2024-05-24 | Atkins Michael B. | Director | A-Award | A | Stock Option (right to buy) | 6,723 | 4.88 | 32.8K | 6,723 | — | ↗ |
| 2024-01-04 | Atkins Michael B. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.25 | 183.8K | 35,000 | — | ↗ |
| 2024-01-02 | Trost Timothy W. | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 4.64 | 696.0K | 150,000 | — | ↗ |
| 2024-01-02 | Seidel-Dugan Cynthia | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 4.64 | 696.0K | 150,000 | — | ↗ |
| 2024-01-02 | Lubman Ellen | Officer | A-Award | A | Stock Option (right to buy) | 131,900 | 4.64 | 612.0K | 131,900 | — | ↗ |
| 2024-01-02 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 4.64 | 696.0K | 150,000 | — | ↗ |
| 2024-01-02 | Isaacs Randi | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 4.64 | 928.0K | 200,000 | — | ↗ |
| 2024-01-02 | HICKLIN DANIEL J | Director / Officer | A-Award | A | Stock Option (right to buy) | 435,000 | 4.64 | 2.02M | 435,000 | — | ↗ |
| 2023-06-21 | Sherman Michael A. | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | D | Stock Option (Right to Buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | Lazarus Alon | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | EVNIN LUKE | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | DiRocco Derek | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-06-21 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.81 | 37.1K | 13,200 | — | ↗ |
| 2023-01-06 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 1,853,000 | 2.21 | 4.10M | 5,701,056 | — | ↗ |
| 2023-01-03 | Trost Timothy W. | Officer | A-Award | A | Stock Option (right to buy) | 102,800 | 0.00 | — | 102,800 | — | ↗ |
| 2023-01-03 | Seidel-Dugan Cynthia | Officer | A-Award | A | Stock Option (right to buy) | 115,900 | 0.00 | — | 115,900 | — | ↗ |
| 2023-01-03 | Lubman Ellen | Officer | A-Award | A | Stock Option (right to buy) | 86,200 | 0.00 | — | 86,200 | — | ↗ |
| 2023-01-03 | Leonard Reid | Officer | A-Award | A | Stock Option (right to buy) | 93,600 | 0.00 | — | 93,600 | — | ↗ |
| 2023-01-03 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 103,600 | 0.00 | — | 103,600 | — | ↗ |
| 2023-01-03 | Isaacs Randi | Officer | A-Award | A | Stock Option (right to buy) | 103,300 | 0.00 | — | 103,300 | — | ↗ |
| 2023-01-03 | HICKLIN DANIEL J | Officer | A-Award | A | Stock Option (right to buy) | 295,500 | 0.00 | — | 295,500 | — | ↗ |
| 2022-06-01 | Sherman Michael A. | Director | A-Award | A | Stock Option (right to buy) | 11,600 | 3.43 | 39.8K | 11,600 | — | ↗ |
| 2022-06-01 | Shah Rajeev M. | Director | A-Award | A | Stock Option (Right to Buy) | 11,600 | 0.00 | — | 11,600 | — | ↗ |
| 2022-06-01 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,600 | 3.43 | 39.8K | 11,600 | — | ↗ |
| 2022-06-01 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 11,600 | 3.43 | 39.8K | 11,600 | — | ↗ |
| 2022-06-01 | Lazarus Alon | Director | A-Award | A | Stock Option (right to buy) | 11,600 | 0.00 | — | 11,600 | — | ↗ |
| 2022-06-01 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 136,000 | 0.00 | — | 136,000 | — | ↗ |
| 2022-06-01 | EVNIN LUKE | Director | A-Award | A | Stock Option (right to buy) | 11,600 | 0.00 | — | 11,600 | — | ↗ |
| 2022-06-01 | DiRocco Derek | Director | A-Award | A | Stock Option (right to buy) | 11,600 | 3.43 | 39.8K | 11,600 | — | ↗ |
| 2022-06-01 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 7,733 | 3.43 | 26.5K | 7,733 | — | ↗ |
| 2022-01-12 | Seidel-Dugan Cynthia | Officer | M-Exempt | D | Stock Option (right to buy) | 15,532 | 4.77 | 74.1K | 83,631 | — | ↗ |
| 2022-01-06 | Trost Timothy W. | Officer | A-Award | A | Stock Option (right to buy) | 65,960 | 11.55 | 761.8K | 65,960 | — | ↗ |
| 2022-01-06 | Seidel-Dugan Cynthia | Officer | A-Award | A | Stock Option (right to buy) | 79,516 | 11.55 | 918.4K | 79,516 | — | ↗ |
| 2022-01-06 | Lubman Ellen | Officer | A-Award | A | Stock Option (right to buy) | 51,088 | 11.55 | 590.1K | 51,088 | — | ↗ |
| 2022-01-06 | Leonard Reid | Officer | A-Award | A | Stock Option (Right to Buy) | 70,967 | 11.55 | 819.7K | 70,967 | — | ↗ |
| 2022-01-06 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 34,258 | 11.55 | 395.7K | 34,258 | — | ↗ |
| 2022-01-06 | Isaacs Randi | Officer | A-Award | A | Stock Option (right to buy) | 79,516 | 11.55 | 918.4K | 79,516 | — | ↗ |
| 2022-01-06 | HICKLIN DANIEL J | Director / Officer | A-Award | A | Stock Option (right to buy) | 215,888 | 11.55 | 2.49M | 215,888 | — | ↗ |
| 2021-12-30 | Leonard Reid | Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,102 | 1.56 | 22.0K | 47,034 | — | ↗ |
| 2021-12-15 | Leonard Reid | Officer | S-Sale | D | Common Stock | 135 | 13.97 | 1.9K | 122,157 | — | ↗ |
| 2021-10-28 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 23,200 | 15.97 | 370.5K | 23,200 | — | ↗ |
| 2021-07-01 | Karunatilake Chulani | Officer | A-Award | A | Stock Option (right to buy) | 272,000 | 19.23 | 5.23M | 272,000 | — | ↗ |
| 2021-06-16 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 9,285 | 13.37 | 124.1K | 4,291,881 | — | ↗ |
| 2021-06-15 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 7,958 | 12.95 | 103.1K | 4,282,596 | — | ↗ |
| 2021-06-14 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 306,055 | 12.75 | 3.90M | 4,274,638 | — | ↗ |
| 2021-06-14 | Karunatilake Chulani | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-27 | Sherman Michael A. | Director | A-Award | A | Stock Option (right to buy) | 23,200 | 14.63 | 339.4K | 23,200 | — | ↗ |
| 2021-05-04 | UPMC | 10% Owner | C-Conversion | A | Common Stock | 273,811 | 0.00 | — | 1,097,756 | — | ↗ |
| 2021-05-04 | Taiho Ventures LLC | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 16.00 | 5.00M | 2,068,909 | — | ↗ |
| 2021-05-04 | Sphera Global Healthcare Management LP | 10% Owner | P-Purchase | A | Common Stock | 475,000 | 16.00 | 7.60M | 787,997 | — | ↗ |
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | C-Conversion | D | Series B Preferred Stock | 2,930,482 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
48.60M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Daniel J. Hicklin, Ph.D. President and Chief Executive Officer | 608.2K | 364.6K | — | 1.56M | — | 12.9K | 2.55M | 61.28% | ↗ |
| 2 | 2024 | Randi Isaacs, M.D. Chief Medical Officer | 494.1K | 215.8K | — | 717.2K | — | 12.9K | 1.44M | 49.80% | ↗ |
| 3 | 2024 | Timothy W. Trost Chief Financial Officer and Treasurer | 466.0K | 199.8K | — | 537.9K | — | 12.9K | 1.22M | 44.21% | ↗ |
| 4 | 2023 | Daniel J. Hicklin, Ph.D. President and Chief Executive Officer | 583.4K | 332.6K | — | 438.6K | — | 12.3K | 1.37M | 32.09% | ↗ |
| 5 | 2023 | Randi Isaacs, M.D. Chief Medical Officer | 474.0K | 216.1K | — | 153.3K | — | 12.3K | 855.8K | 17.92% | ↗ |
| 6 | 2023 | Timothy W. Trost Chief Financial Officer and Treasurer | 447.0K | 203.8K | — | 152.6K | — | 12.2K | 815.6K | 18.71% | ↗ |
| 7 | 2022 | Daniel J. Hicklin, Ph.D. President and Chief Executive Officer | 530.4K | 275.3K | — | 1.66M | — | 11.6K | 2.47M | 66.98% | ↗ |
| 8 | 2022 | Randi Isaacs, M.D. Chief Medical Officer | 442.0K | 183.5K | — | 581.7K | — | 11.6K | 1.22M | 47.72% | ↗ |
| 9 | 2022 | Cynthia Seidel-Dugan, Ph.D. Chief Scientific Officer | 416.0K | 172.7K | — | 610.5K | — | 11.6K | 1.21M | 50.42% | ↗ |
| 10 | 2022 | Timothy W. Trost Chief Financial Officer and Treasurer | 399.0K | 165.7K | — | 506.4K | — | 11.6K | 1.08M | 46.77% | ↗ |
| 11 | 2021 | Chulani Karunatilake, Ph.D. Chief Technology Officer | 214.2K | 128.0K | — | 3.52M | — | 1.2K | 3.86M | 91.11% | ↗ |
| 12 | 2021 | Daniel J. Hicklin, Ph.D. President and Chief Executive Officer | 498.5K | 263.0K | — | 1.70M | — | 1.4K | 2.46M | 69.02% | ↗ |
| 13 | 2021 | Timothy W. Trost Chief Financial Officer | 337.8K | 142.0K | — | 1.61M | — | 1.3K | 2.09M | 76.98% | ↗ |
| 14 | 2021 | Randi Isaacs, M.D. Chief Medical Officer | 411.8K | 276.0K | — | 621.0K | — | 1.4K | 1.31M | 47.40% | ↗ |
| 15 | 2021 | Cynthia Seidel-Dugan, Ph.D. Chief Scientific Officer | 387.0K | 165.0K | — | 633.3K | — | 1.4K | 1.19M | 53.37% | ↗ |
| 16 | 2020 | Daniel J. Hicklin, Ph.D. President and Chief Executive Officer | 425.0K | 193.9K | — | 2.37M | — | — | 2.99M | 79.30% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel J. Hicklin | Founder, Chief Executive Officer, President, Secretary & Director | 645.6K | — |
| Michael Urban | VP of Finance, Corporate Controller, Principal Financial Officer & Principal Accounting Officer | — | male |
| Steven H. Bloom | Chief Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HOWL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
